NASDAQ:STML - Stemline Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.39 +0.02 (+0.18 %)
(As of 11/18/2018 03:45 PM ET)
Previous Close$11.39
Today's Range$11.24 - $11.65
52-Week Range$11.08 - $20.55
Volume391,378 shs
Average Volume222,093 shs
Market Capitalization$362.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STML
Previous Symbol
CUSIPN/A
Phone646-502-2311

Debt

Debt-to-Equity RatioN/A
Current Ratio4.65
Quick Ratio4.65

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$900,000.00
Price / Sales402.45
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book5.70

Profitability

EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net MarginsN/A
Return on Equity-114.50%
Return on Assets-90.21%

Miscellaneous

Employees37
Outstanding Shares31,800,000
Market Cap$362.21 million
OptionableOptionable

Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.06. View Stemline Therapeutics' Earnings History.

When is Stemline Therapeutics' next earnings date?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Stemline Therapeutics.

What price target have analysts set for STML?

4 brokerages have issued 1-year price targets for Stemline Therapeutics' shares. Their forecasts range from $22.00 to $38.00. On average, they expect Stemline Therapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

What is the consensus analysts' recommendation for Stemline Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

Has Stemline Therapeutics been receiving favorable news coverage?

Press coverage about STML stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the near term.

Who are some of Stemline Therapeutics' key competitors?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 52)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
  • Robert Francomano, Global Head of Commercial

Who are Stemline Therapeutics' major shareholders?

Stemline Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.36%), FMR LLC (5.01%), Nexthera Capital LP (1.83%), Point72 Asset Management L.P. (0.82%), C WorldWide Group Holding A S (0.58%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Which institutional investors are selling Stemline Therapeutics stock?

STML stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, C WorldWide Group Holding A S, Virtus ETF Advisers LLC, Rhumbline Advisers, Los Angeles Capital Management & Equity Research Inc. and Dimensional Fund Advisors LP. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.

Which institutional investors are buying Stemline Therapeutics stock?

STML stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Nexthera Capital LP, BlueMountain Capital Management LLC, Neuberger Berman Group LLC and MetLife Investment Advisors LLC. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy shares of Stemline Therapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $11.39.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $362.21 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Stemline Therapeutics employs 37 workers across the globe.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is http://www.stemline.com.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel